C-CHHWChronos Therapeutics
orexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CHHW
C-CHHWC-CHHWorexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Dr Huw Jones, CEO of TheraCryf plc explains to focusIR about why the latest toxicology results represent a major milestone on the path to human clinical trials. #TCF #Biotech #ClinicalTrials
Dr Huw Jones, CEO of TheraCryf plc, talks about the key hurdles that the Company has overcome with the Ox-1 blocker programme. #TCF #Biotech #ClinicalTrials
Dr Huw Jones, CEO of TheraCryf plc, provides an insight on why successful manufacturing scale-up and a new patent filing materially strengthen the programme’s commercial value. #TCF #Biotech #ClinicalTrials
TheraCryf plc (TCF) is a biotechnology company developing novel treatments for addiction and other neuropsychiatric disorders. Its lead Ox-1 blocker programme is advancing toward first-in-human studies, targeting major unmet needs across substance use disorders and binge eating disorder. Following the announcement of positive top-line toxicology data, CEO Dr Huw Jones joins Focus IR to discuss the scientific progress, commercial potential and upcoming catalysts for the business. In this interview, investors will hear: - Why the latest toxicology results represent a major milestone on the path to human clinical trials - How the Ox-1 blocker demonstrated strong tolerability at doses up to 100 times the expected human therapeutic level - Why successful manufacturing scale-up and a new patent filing materially strengthen the programme’s commercial value - How TheraCryf is positioning itself for future licensing opportunities in the fast-growing addiction and neuropsychiatric marke
TheraCryf (AIM: TCF) is advancing its lead asset OX1 with a newly secured process patent that could extend exclusivity to 2046, while also achieving successful GMP manufacturing ahead of clinical trials. CEO Huw Jones discusses how aligning intellectual property protection with scalable manufacturing strengthens the company’s position as it approaches clinical readiness in 2026. This discussion covers: - OX1’s role in targeting substance use disorders and its $70B market potential - New patent protection extending exclusivity to 2046 - Successful GMP manufacturing and early production milestones - Scalability progress and implications for future partnerships - How IP and manufacturing alignment enhances licensing potential Website: https://theracryf.com This video is made in partnership with TheraCryf. This video is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://stockhouse.com/legal/disclaimer #Biotech #Investing #Pharma
TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders (*orphan indication). Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has industry partnerships with companies including Stalicla SA, in neurodevelopmental disorders. Presenters: Dr Huw Jones, CEO Huw has over 30 years’ experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on preclinical and clinical drug development, dilutive and non-dilutive financing and business development. Most recently he was a Non-executive Director of Ixaka Ltd and Chairman of Chronos Therapeutics Ltd.
The purpose of this study is to characterise the pharmacokinetics, safety and tolerability of RDC5 given as a single dose to healthy volunteers at a number of different dose levels
Final Results - Correction | Company Announcement | Investegate Fundraise Welcome About Contact Us Help Home Companies Advanced search Archive UK Short Positions Meetings UK Newswire New Login Register Final Results - Correction Theracryf PLC 28 May 2024   This announcement replaces the Final Results announcement released at 07:00 on 28 May 2024 and includes a correction to the cash outflow bullet in the financial highlights. The line should read:  Cash outflow from operations of £3.4m (2023: outflow of £4.9m).     TheraCryf plc ("TheraCryf", the "Company" or the … o 31 March 2024.   Operational Update ·      Grant awarded by the Netherlands government administered by the Dutch Cancer Society for pre-clinical work and a clinical trial in glioblastoma (GBM) led by Dr Marjolein Geurts, Erasmus MC, Rotterdam, €1.1m project o  Activity of SFX-01 in GBM cells from Netherlands' patients corroborating previous data from academic partners in Italy and New Zealand ·      … 0;  Regulatory work and approvals in support of GBM clinical trial via the grant to Erasmus MC, Rotterdam ·      Completion of integration of Chronos Therapeutics Ltd ·      Grant of further patents for former Chronos programmes ·      Non-dilutive Grants sought for acquired Ox-1 and DAT programmes ·      Publication of clinical paper on SFX-01 Phase 1b … period end have been transformative for the Company. We succeeded in securing a grant for our lead clinical asset in GBM leading to a grant funded clinical trial in patients with this devastating disease in 2026. We observed activity of SFX-01 in models of another cancer, colorectal and have seen further corroborative evidence of SFX-01 effectiveness in GBM models in a third academic centre. Our Phase 1b healthy volunteer study using our commercial grade tablet of SFX-01 was … s indication as an investigator sponsored study in the Netherlands funded via a grant from the Netherlands government to the Erasmus Medical centre, Rotterdam. TheraCryf has a wide number of collaborations with leading academic centres in the UK, Europe and USA. The Company completed an out-licensing transaction in 2022 with Stalicla SA, a Swiss
Board of Directors :: Oxford BioDynamics PLC (OBD) --> Skip to main content Skip to section navigation Skip to footer Store Careers Contact Us Search Search Search Assets Home About Us Overview Historical Timeline Leadership Team Board of Directors Advisory Panel Products & Services Overview EpiSwitch CiRT EpiSwitch PSE EpiSwitch ME/CFS EpiSwitch Orion EpiSwitch Explorer Specimen Submission Kit OBD Store EpiSwitch® Platform Media Center In the News In the Loop Regulatory News Publications Investors Overview News & Events Company Info Financial Results Stock Data AIM Rule 26 Governance … he USSR. In 1989, he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students. He obtained his PhD in cell bio logy from University College, London (with the research-based at the Imperial Cancer Research Fund). He then spent six years at the Robert Wood Johnson Medical School-UMDNJ, NJ, as a research assistant funded by the Howard Hughes Medical Institute. Upon his return to Engla … es Investment Management, and Chairman and director of the Vulpes Life Sciences fund. He has extensive experience in the life sciences sector and has served on the Board of several public and privately listed companies such as Oxford Biomedica, Scancell, Proteome Sciences, Leucid Bio, Chronos Therapeutics and Oxford Endovascular. Prior to Vulpes, he was a Partner and Director of UBS/Brunswick. Before that, he spent 7 years at Morgan Stanley. Martin graduated from the Universi … g at MTI Ventures LLP, Director, Life Sciences at the Cambridge University Seed Fund and July 2021, Senior Independent Director at Worldwide Healthcare Trust plc. David was appointed to the OBD Board in April 2019. He chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. Peter Presland LL.B, ACA Non-Executive Director Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of t … he USSR. In 1989, he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students. He obtained his PhD in cell bio logy from University College, London (with the research-based at the Imperial Cancer Research Fund). He then spent six years at the Robert Wo
Polleo Pharma co-founders join Chronos Therapeutics - PMLiVE Advertise Subscribe Contact Publications PME PME supplements Communique T40 Follow Follow Follow Follow News Research Sales Regulatory Healthcare Marketing Intelligence Intelligence Webinars Podcasts Digital Handbook Orphan drugs & rare diseases Glossary Healthcare Advertising Gallery Thought Leadership Appointments Awards Blogs Digital intelligence Smart Thinking Darwin’s Medicine Webinars T40 Top 40 overall Smaller agencies Independent agencies Young agencies UK focused agencies About T40 Top Pharma list PMHub Company Profiles
Chronos Therapeutics strengthens management team with two appointments Home Categories Ingredients Analysis Manufacturing Finance Company News Regulatory Drug Delivery Research & Development Sustainability Pharma 5.0 Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Manufacturing Chemist Home Careers Chronos Therapeutics strengthens management team with two appointments Chronos Therapeutics strengthens management team with two appointments Dr Fraser Murray and Dr Timothy Schulz-Utermoehl join the firm as Vice Presidents of … n and dermatology. Prior to co-founding Polleo Pharma and raising investment to fund the portfolio, Dr Murray was Senior Director and Head of Discovery Biology for Shire Speciality Pharmaceuticals, focused on CNS and GI disorders. Dr Schulz-Utermoehl has more than 17 years of experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. Prior to co-founding Polleo Pharma, Schulz-Utermoehl was a director within the Exp
Final results for year to 31 March 2025 | Company Announcement | Investegate Fundraise Welcome About Contact Us Help Home Companies Advanced search Archive UK Short Positions Meetings UK Newswire New Login Register Final results for year to 31 March 2025 Theracryf PLC 03 June 2025       TheraCryf plc ("TheraCryf", the "Company" or the "Group")   Final Results for year to 31 March 2025   Alderley Park, 3 June 2025   - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain diseases,  announces its full year results for the year … on of SFX-01 in vitro work by Erasmus Medical Centre Rotterdam NL, as part of a grant funded study in glioblastoma, start of in vivo pre-clinical work. ·   Constructive and amicable discussions continuing towards resolution of dispute with partner Stalicla SA. Financial summary ·   Post tax loss of £1.9m (2024: loss of £3.1m). ·   Cash outflow from operations of £2.4m (2024: outflow of £3.0m). ·   … X-01 asset is expected to enter the clinic in 2026 fully funded externally by a grant. I have been impressed with the integrity of the management team and board, and the clear commitment to maximising value from R&D in as capital efficient business model as possible, and to putting the interests of shareholders first. In this spirit, all members of the board and management team have voluntarily reduced their salaries in the reporting year and have again foregone opportuni … oss in February 2025) to take the first Chronos asset to the stage where we can submit an application to take our class leading orexin-1 antagonist to the point of readiness for human clinical trials.   This process will complete in late 2026 and will consist of optimising and scaling up of the manufacturing process to kilogram scale. The second part of the completion of pre-clinical development, also by late 2026, will be to conduct two toxicology studies, each lasting … ll listed European Biotech companies as measured by months of remaining cash to fund operations. Post period, we have appointed Pharmaron UK Ltd as our contract development partner in order to deliver this work which has already started in earnest.   Priority Programme Ox-1 We believe that our orexin-1 blocker is the most selective yet disco
Events And Meetups | MelloLondon Returns To Chiswick On 18th & 19th November | Carmensfella --> Login Get Started 15 MelloLondon returns to Chiswick on 18th & 19th November 6th Aug '25 by carmensfella 35 comments 1181 reads There has always been a good following of our events/conferences here on Stockopedia! We are pleased to announce that we have launched the next edition of MELLOLONDON Do join us for another two-day investor conference in Chiswick, West London, bringing together engaged private investors & 50 quality UK listed companies under one roof. Mello is the only place to get dire … November. 2 Reply carmensfella 20th Oct '25 Hugh Hendry the legendary ex Hedge Fund manager will also be joining us for an interview in the MelloTheatre 2 Reply carmensfella 22nd Oct '25 Another five companies announced as attending MelloLondon tomorrow and a few Stockopedia favourites amongst them. Also a new headline guest speaker...the ex hedge fund guru Hugh Hendry who is a real character and will be joining us on the 19th November Investor Education, Networking & Pr … pedia favourites amongst them. Also a new headline guest speaker...the ex hedge fund guru Hugh Hendry who is a real character and will be joining us on the 19th November Investor Education, Networking & Presentations - MelloLondon will have it all. I am sure many of the Stockopedia community will be there - for Mello2025 we were lucky enough to welcome the likes of Ed Croft, Graham Neary, Mark Simpson & more from the Stockopedia contributor list! We will also have mus
Physics of Life Physics of Life Physics of Life About Committee Registration Registration Visas Bursaries Programme Programme Satellite Events Submission Topics Speakers - Overview Speakers - Overview Keynote Speakers Invited Speakers Venue Hotels Exhibition Exhibition Confirmed Exhibitors Floor Plan Sponsorship Sponsorship Sponsors Guidelines Guidelines Oral Presenters Poster Presenters Attendee Guidelines Exhibitor Guidelines Contacts (UTC+00:00) Dublin, Edinburgh, Lisbon, London Jane Mellor Professor Jane Mellor is a lecturer and full professor in the Department of Bio … England and Wales (no. 293851) and Scotland (no. SC040092) Agenda × Clear Apply × Close
%PDF-1.4 %���� 1 0 obj > endobj 6 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 7 0 obj > >> /MediaBox [0.0 7.8299813 1190.25 850.07996] /Contents 13 0 R /StructParents 0 /Tabs /S /Parent 2 0 R /BleedBox [0.0 7.8299813 1190.25 850.07996] /TrimBox [0.0 7.8299813 1190.25 850.07996] /CropBox [0.0 7.8299813 1190.25 850.07996] /Rotate 0 /Annots [] >> endobj 8 0 obj > >> /MediaBox [0.0 7.8299813 1190.25 850.07996] /Contents 16 0 R /StructParents 1 /Tabs /S /Parent 2 0 R /BleedBox [0.0 7.8299813 1190.25 850.07996] /TrimBox [0.0 7.8299813 1190.25 850.07996] /CropBo
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 7 0 obj > stream x��ZyXU� vd� YT!�� "DL�F�B1ƚhc�1�F�ø�A�T�*��CTR�QQj��ZQ����,�f�^��-ә�ۻ |� �� �sfΙ{~wf�,z�kz������{�v#��֧싧�/�Z:� 2 �U8���ʍ�-�!�z8�����a�dh`�xJ�_���,m:2��k��d���a�dh��\T� �H��9�mE�Vu�!�!A\%Q� .��Ko���[͡ �0)$ N�x�f���c|f!u��8�%O�g����i�%K@Ŭ�RHPPP���j��[có2���� ^�C��֖ĭA^_�PC��8�Թ�}_�Va�0[�=�L�O1 n'�����[B}g��e�(���.�t�L��\G��'�I� �Ɔ�l�E��=A T���rſ-������F&�` �����0?Z�K s��.�"X�'�ϸ�� �]}��:�XX�,1��G��w ���� �σ��|��5�p��Gh�T� ���_]�82r��l�كK� &IP {��R�BA�ގpB0�#4,�
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 44 0 obj > stream x��V�nI��W�iU�bz+�� ��`׀1�Zh��� �[���=3��� � ���Y�3�'�������gN> �B%� ��ObV� ��I�Vg�ywg … ��|���t\�� .��� L��� � P��&��[3��L]�"u�>�EL�T@6 �v� �悤!^�.ta\H ���Y]�j ~��{Rfps�ruz���l&�"'�� �f��O�B�l����9hJ 1e�j�YmfԷ��^�_'�o�ף�aR1�/ ����s!�X(6���c��|r� ���᭖���B��=���a�y�= ���t@5� }��YBqct �(�B�����Hc�ŊCo�@�+��d�V�B��E��Mu��n�=S&�q����)��b�� �����}�[HÃ�cg�u0c�i���8Y�H(X\l�) �a�|t2 �� uS#���4� x���� 44* q ΅����4x���l����kr%�٩ $���[��@p"c�!�� /8� � �#�?rDb�/0�� �0@)���Ҭ����)��� �x��#��ډ�B��B� I7 l�yԆU0��!��"$N(��˅xc;8V!����X
%PDF-1.7 %���� 653 0 obj > endobj xref 653 2322 0000000016 00000 n 0000054825 00000 n 0000055037 00000 n 0000085797 00000 n 0000085832 00000 n 0000085972 00000 n 0000086111 00000 n 0000086159 00000 n 0000086281 00000 n 0000086395 00000 n 0000086550 00000 n 0000086599 00000 n 0000086648 00000 n 0000086697 00000 n 0000086746 00000 n 0000086795 00000 n 0000086843 00000 n 0000086892 00000 n 0000086940 00000 n 0000086988 00000 n 0000087037 00000 n 0000087086 00000 n 0000087134 00000 n 0000087182 00000 n 0000087230 00000 n 0000087278 00000 n 0000087326 00000 n 0000087374 00000 n 0000087423 00000 n 0 … Rd��� b��A�C��9��r�Ԑ�2sӯ��L6CG`�h������ڱ��l�9�ᣤ O�찮�=�Pl�#VN �� ���cNԷrfP�4 �eJ� opX�N�%� �E��s_#��2��]\E� �S�"� �9���{7g/+���#5�y�������9����`�� �(L�byq��/FN�d_�������Ӗ�^>��hk1�[q���i7�4� �Wi�����\.��If%��� $�����|�-������6.�\�t^��!C��� Сj|� �⁼����j2�aŏ��t#�� �9|ܑ��#�{� �� ����qE�b��� u��]�sգ�'�S�{�;=��A�U�~�9�x�fϏ���� �I�� /��.4� E^�"�Z���R�� �ȷ&:N����w} �R���U���:�a�&��'$����;� '�-2u��$dUi�� v����G�� ���O�س�����,1�t��=� … ����}�0T �8��.+��)��L�ۏ��t�f(�D�3����,Ի}���x)���ͫ30�ydb���T7 �g��-� S��g;��rfp�xA݆��)G�)3V�tS�U���Ԛ�CMA�I6���$N��L��X.� �_�3D��y��E+W�"�%w��q�є&�2�R�j�l���p��S�X���{��"���� �P�' 4�R=�(��Gv� G��@�>VȂ��j�\%���/�_UR��~q��K�j4 �2���QF"? 3]z��va����뤱��|կC|�\{-�M�� *������ ���jD�}�P��EWe�w�T RVK�.�f�1��`#=^}/m�[K�te0$��E[(�Q�g_W28�J" �g�>s8%��ob���꜠g�� ��6�jlA�7dp�J�t^W���� �س�r������9�CT#�C�#����}b�fU���Wi���3�o�WT��:ưJ~����Ѫ�7�)�Ҩ�OrkG1� ${; �� … ��.� endstream endobj 2965 0 obj > endobj 2966 0 obj >stream H�\��n� �� >stream application/postscript Task PPD 05v4 Akash 2017-01-10T14:44:14+05:30 2017-01-10T14:44:14+05:30 2017-01-10T14:44:10+05:30 Adobe Illustrator CS6 (Windows) xmp.iid:9375B3E514D7E611A9B2DB94601FBAE8 xmp.did:9375B3E514D7E611A9B2DB94601FBAE8 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9275B3E514D7E611A9B2DB94601FBAE8 xmp.did:9275B3E514D7E611A9B2DB94601FBAE8 uuid:5D20892493BFDB11914A8590D31508 … �i2 O endstream endobj 521 0 obj > endobj 522 0 obj > endobj 523 0 obj >stream application/postscript Task PPD 05v4 Akash 2017-01-10T14:44:14+05:30 2017-01-10T14:44:14+05:30 2017-01-10T14:44:10+05:30 Adobe Illustrator CS6 (Windows) xmp.iid:9375B3E514D7E611A9B2DB94601FBAE8 xmp.did:9375B3E514D7E611A9B2DB94601FBAE8 uuid:5D20892493BFDB11914A8590D315
Upcoming conferences | Company Announcement | Investegate Fundraise Welcome About Contact Us Help Home Companies Advanced search Archive UK Short Positions Meetings UK Newswire New Login Register Upcoming conferences Evgen Pharma PLC 13 November 2023   Evgen Pharma plc ("Evgen" or the "Company")   Attendance at upcoming investor conferences   Alderley Park, UK - 13 November 2023 : Evgen Pharma plc (AIM: EVG), a clinical stage drug development  company   developing sulforaphane-based medicines for the treatment of cancer and other indications , notes that members of its … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock
TheraCryf PLC Share News, Key Dates and Documents | TCF | GB00BSVYN304 | Fidelity TheraCryf PLC (TCF) Industry Biotechnology Deal This stock can be held in an Investment ISA, SIPP and Investment Account Sell 0.21p Buy 0.22p Change arrow-down -0.02p (-8.51%) Prices updated at 26 Jun 2026 , 15:53 BST | Prices minimum 15 mins delay | Prices in GBX TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships f . … e 16 Apr 2026 New Manufacturing Process Patent for Ox-1 14 Apr 2026 Non-Binding Proposal to Acquire TheraCryf’s Assets 26 Jan 2026 Ox-1 Addiction Programme Update 05 Jan 2026 Key Ox-1 milestone & notice of investor webinar 18 Dec 2025 Potential of Preclinical Program in Mental Fatigue 03 Dec 2025 Half-year Financial Report Key dates Forecast date Half yearly results Dec 2026 Annual general meeting Jul 2026 Annual report Jul 2026 Final results Jul 2026 Previous date Half y
%PDF-1.7 %���� 1 0 obj >/Metadata 793 0 R/ViewerPreferences 794 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 29 0 R 30 0 R 31 0 R] /MediaBox[ 0 0 594.96 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}is9�������/�KNX��UDŽñ����3��ޝ��~ (���,�l����o��n ��,�,��g�e `e"䝉���z:ۍ�??��Mg��ѯ� W�� ���OG�~����h���o�1�J�%�逍L+��а�t� BZ&Fv�ir���ͧI6��&gj�X�ߛ� �^O�xu� ��r�_̦0J�a;�^aU����/�I^h8&�_�=$D�d����>:�@��3�M������E�*S&B���W��6�曮'gf��}9�-p�mGSz?�e��x�iR��:b�� ��A����O 9��vg�@���X
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��[I�^YVd�� � ������]��6r���lX�X%i�ł�OD�;�/����yN�;�!N�!� ����ߗo��7w���ߒ���-� �~����n�x�����
Chronos Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 30 Apr 2026 Chronos Therapeutics Ltd. Subsidiary Company | 2009 | United Kingdom | 10-50 | www.chronostherapeutics.com Subsidiary Company | 2009 | United Kingdom | 10-50 | www.chronostherapeutics.com Last update 30 Apr 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Nervous System Diseases Small molecule drug Disease domain score A glimpse into the focused therape … ial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on t … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Chronos CEO Huw Jones wins award Home Categories Ingredients Analysis Manufacturing Finance Company News Regulatory Drug Delivery Research & Development Sustainability Pharma 5.0 Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Manufacturing Chemist Home Careers Chronos CEO Huw Jones wins award Chronos CEO Huw Jones wins award Huw Jones has won Best CEO in the European Drug Discovery Industry Dr Huw Jones, CEO of Chronos Therapeutics Ltd, been awarded Best CEO, 2016. He is one of six finalists nominated anonymously for the … of six finalists nominated anonymously for the European Drug Discovery Industry award last year. “We are developing a re-purposed asset for the devastating disease ALS and actively searching for more discoveries in neurodegeneration,” Jones said. “This award recognises Chronos’ team effort in developing and acquiring treatments for patients with degenerative and behavioural diseases.” Chronos Therapeutics is a privately held biotechnology company focused on diseases of ageing
Dr Huw Jones, Executive Director - TheraCryf Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us Dr Huw Jones, Executive Director steve | 3 December 2021 Categories: Post navigation Toni Haenninen, Executive Director → Copyright © 2026 ICO Reg: ZB396415 Company Number: 09246681 Website Privacy Policy and Cookie Policy Sitemap Get in touch
About | Therapeutics in oncology and behavioural brain disorders Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us About Us TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. TheraCryf’s leadership team has decades of corporate, financial and scientific experience in … leading the creation and delivery of the £180m Biomedical Catalyst competitive grant scheme, whilst at Innovate UK. In addition to her role in TheraCryf she is an Operating Advisor with SymBiosis Capital Management, a US based healthcare focused venture fund, and an independent board member of the University Commercialization Executive Board at the University of Bath. Helen holds a PhD in physiology and pharmacology from the University of Leicester, UK. Dr Glen Clack Chief M … nd articulate their value. As Founder-Director and Chief Creative Officer of an award-winning immersive technology company, he led strategy, technology development and brand positioning. Edward currently serves in executive and advisory roles with AIM-listed Ironveld PLC and investment firm Northern Standard, where he works closely with boards and management teams on market positioning, stakeholder engagement, and growth strategy. He is also on the board of N4 Pharma PLC. A g
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 28 0 obj > stream x��TMo1�8pi] ��(mY�C�!J���d�mhſ獳i"!$����y�ͳ�k�ʐ�g �Kqt�4-��bЮ f�)�b�֡а�\�� O'=�+��I�a
TheraCryf PLC, TCF:LSE summary - FT.com Subscribe Sign In Menu Search Financial Times myFT if you don't need to support both core and enhanced --> Search the FT Search Search the FT Search Close Home World US Companies Tech Markets Climate Opinion Lex Stock Picking Game Life & Arts How To Spend It Sign In Subscribe Markets Markets Data Equities Equities Screener Sectors & Industries Company Announcements Director Dealings World Markets Financial Times Close International Edition UK Edition Search the FT Search Top sections Home Show more World link World Middle East war Global Economy … al opportunities. Find Stocks Similar to TCF Go to the Equities Screener Apply Cancel Actions Add to Your Watchlists New watchlist Name Cancel Add Add to Your Portfolio New portfolio Name Currency Select a currency UK Pound (GBP) Argentinian Nuevo Peso (ARS) Australian Dollar (AUD) Bahraini Dinar (BHD) Brunei Dollar (BND) Brazilian Real (BRL) Canadian Dollar (CAD) Chilean Peso (CLP) Chinese Yuan Renminbi (CNY) Czech Koruna (CZK) Danish Krone (DKK) Egyptian Pound (EGP) … ings Financials Forecasts Historical prices More 1D 3D 1W 1M 6M 1Y 3Y 5Y Compar Apply Cancel Comparisons Make up to three selections, then save. 0 of 3 selected 0 of 3 selected Suggested Comparisons ValiRx Plc Futura Medical PLC ImmuPharma PLC IXICO PLC Thalia Therapeutics PLC OptiBiotix Health PLC Fusion Antibodies PLC Cizzle Biotechnology Holdings PLC Arecor Therapeutics PLC Solvonis Therapeutics PLC Genflow Biosciences PLC Cardiogeni PLC Save Clear Go to Interactive chart … c Apr 20 2026 New Manufacturing Process Patent for Ox-1 Apr 16 2026 Non-Binding Proposal to Acquire TheraCryf’s Assets Apr 14 2026 Ox-1 Programme Advances to Final Toxicology Study Mar 23 2026 More ▼ TCF:LSE trading volume exceeds daily average by +62.85% Jun 26 2026 TCF:LSE price moved over -6.38% to 0.22 Jun 26 2026 TCF:LSE price falls below 200-day moving average to 0.2131 at 14:14 BST Jun 26 2026 TCF:LSE price falls below 50-day moving average to 0.23 at 10:25 BST
TheraCryf Final Results for year to 31 March 2025 | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
TRADING UPDATES: Theracryf spurns offer; Cobra's 'encouraging' results | AJ Bell Skip to main content Breadcrumb Home News and insights TRADING UPDATES: Theracryf spurns ... Header Bar About us Contact us & help Adviser platform Recent searches Search Investing ISAs Pensions News & Insights Help & Education New to AJ Bell? My account Access your account options Log out Login Recent searches Search My account Close my account navigation menu Menu Open navigation menu Close navigation menu Our accounts Our accounts Stocks & shares ISA Our most popular tax-free inve … ansfer your money to the seven-time Which? recommended platform Pension builder fund The classic, balanced fund designed for long-term, stable growth Pension essentials A library of guides to help you build a pension that works for you What is a SIPP? Understand the finer points of opening and managing a SIPP Pension calculator See how much your pension could be worth Approaching retirement Approaching retirement Accessing your pension Your pension options explained, to get y … ansfer your money to the seven-time Which? recommended platform Pension builder fund The classic, balanced fund designed for long-term, stable growth Pension essentials A library of guides to help you build a pension that works for you What is a SIPP? Understand the finer points of opening and managing a SIPP Pension calculator See how much your pension could be worth Accessing your pension Your pension options explained, to get you ready for retirement Drawdown Unlock flexib … r a new programme within Numab Therapeutics’ oncology pipeline. Physiomics will apply quantitative approaches to interpret emerging data, optimise experimental design and development strategy, and inform key go/no-go decision-making. ‘This project further strengthens Physiomics’ established collaboration with Numab Therapeutics and highlights the ongoing integration of model-informed approaches to support strategic decision-making across Numab Therapeutics’ pipeline,’ company … on cancer and brain disorders - Rejects a conditional, non-binding, indicative proposal regarding the potential acquisition of TheraCryf’s lead neuropsychiatry assets, namely the Orexin-1, and dopamine transporter programmes. Comments: ‘Following careful consideration, the board unanimously concluded that the indicative proposal did not reflect
THERACRYF | Acquisition, Fundraising and Change of Name Home StockRanks™ Platform Insights Research & Discuss Editorial & Community Learn & Improve Webinars & Masterclasses Stockopedia Academy Reviews Pricing Get started Log in Sectors Healthcare Biotechnology & Medical Research Theracryf TCF — Theracryf News Story 0.24p 0.00 0.00% Last trade - 00:00 Healthcare Highly Speculative Micro Cap Momentum Trap Market Cap £5.05m Enterprise Value £1.55m Revenue Quality Value Momentum Stock Rank ™ StockReport™ Accounts Balance sheet Income statement Cashflow statement Dividend summar … to continue to optimise manufacturing for lead clinical stage asset SFX-01 and fund the maintenance of the acquired Chronos Therapeutics patent portfolio. Working capital will be used to support the search for non-dilutive funding for development of the acquired assets CT-010018 and CT-05404. 4. Current Trading and Outlook In the last twelve months the Company has completed an insightful Phase 1/1b volunteer study and continues to analyse gene expression data from the study. … d distributions declared, made or paid on or in respect of the Ordinary Shares. Application for Admission Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Subject to, amongst other things, Shareholder approval of the Resolutions at the General Meeting, Admission will be effective and dealings in the New Ordinary Shares on AIM are expected to commence, at 8.00 a.m. on 5 April 2024 (or such later date as may be … up take of the Retail Offer APPENDIX IV - DEFINITIONS The following definitions apply throughout this announcement, unless the context otherwise require": "Act" the Companies Act 2006 (as amended) "Acquisition" the acquisition of the entire issued share capital of Chronos Therapeutics pursuant to the terms of the Acquisition Agreement "Acquisition Agreement" the conditional share purchase agreement dated the date of this Announcement between (1) certain Chronos Shareholders ( … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] (mailto:[email protected]) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
£4.25m Placing and Subscription, Notice of GM | Company Announcement | Investegate Fundraise Welcome About Contact Us Help Home Companies Advanced search Archive UK Short Positions Meetings UK Newswire New Login Register £4.25m Placing and Subscription, Notice of GM Theracryf PLC 19 February 2025   THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRIC … n readiness for administration to Glioblastoma (GBM) patients in 2026 under the grant programme to the Erasmus Medical Centre, Rotterdam, Netherlands. The remainder of the proceeds will be for maintenance of the Company's patent portfolio, to fund the key consultants and advisers necessary to complete the Ox-1 programme and for general corporate purposes, including maintaining a listing as a public company. The Fundraising will ensure that the Company's cash runway is extende … 00 new Ordinary Shares in April 2025.   Admission, Settlement and Dealings Application will be made to London Stock Exchange plc (" London Stock Exchange ") for admission of the Firm Placing Shares and, subject to the passing of the Fundraising Resolutions, application will be made to London Stock Exchange for the admission of the Conditional Placing Shares and the Subscription Shares, to trading on AIM, being the market of that name operated by London Stock Exchange. In … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock
Helen Kuhlman promoted to COO at TheraCryf, advancing Orexin-1 antagonist programme | CXO Lanes (UK & Europe) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cli
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Theracryf plc - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
--> Chronos Therapeutics acquisitions bring hope for diseases of ageing – European CEO --> Search for: --> Sign up for the newsletter › --> › Digital Editions Profiles Industry Outlook Management Finance World View Lifestyle Videos Awards Search for: MENU Profiles Industry Outlook Management Finance World View Lifestyle Videos Awards Digital Editions --> Chronos Therapeutics acquisitions bring hope for diseases of ageing ALS, MS fatigue, addictive behaviours and PTSD are all under the drug discovery lab's microscope Post navigation Previous video › Podcasts make radi
TheraCryf CEO Discusses Ox-1 Toxicology Data and Human Trials | London South East posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
Two Former Shire Execs Join Chronos Therapeutics as New VPs for Multiple Schlerosis and PTSD Research - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Two Former Shire Execs Join Chronos Therapeutics as New VPs for Multiple Schlerosis and PTSD Research August 4, 2016 | 2 min read Twitter LinkedIn Facebook Email Print Chronos Therapeutics Strengthens Management Team with Appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl as Vice … aZeneca and Merck. Prior to co-founding Polleo Pharma and raising investment to fund the portfolio, Dr Murray was Senior Director and Head of Discovery Biology for Shire Speciality Pharmaceuticals, focused on CNS and GI disorders. Dr Murray holds a PhD from The School of Pharmacy UCL, a BSc from the University of Strathclyde and an MBA from Alliance Manchester Business School. Timothy Schulz-Utermoehl Dr Schulz-Utermoehl has over 17 years’ experience in the pharmaceutical ind … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Chronos Scoops Up Three Pre-clinical Programs From Shire for Undisclosed Sum - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Chronos Scoops Up Three Pre-clinical Programs From Shire for Undisclosed Sum July 20, 2016 | 6 min read Twitter LinkedIn Facebook Email Print Chronos Therapeutics Acquires Pre-clinical Programmes From Shire OXFORD, England , July 20, 2016 /PRNewswire/ -- Expands Pipeline With Novel CNS Assets in … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Investor Meet Presentation - Proposed Acquisition - TheraCryf Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us Investor Meet Presentation – Proposed Acquisition of Chronos Therapeutics Ltd, Placing and Accompanying Retail Offer mel | 21 March 2024 Categories: Videos Post navigation ← TheraCryf “delighted” with cash position after promising first half TheraCryf plc Full Year Results → Copyright © 2026 ICO Reg: ZB396415 Company Number: 09246681 Website Privacy Pol
#snoasco23 | TheraCryf LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip to m
Orexin 1R antagonist patent granted, new formulation and preclinical studies underway | TheraCryf posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue t … TheraCryf 1,652 followers 9mo Report this post Today, we've announced a patent grant and positive development programme update for our lead asset Orexin 1R antagonist in addiction. 💡Notification of a Decision to Grant a Patent, covering the lead compound and associated structures, from the Korean Intellectual Property Office, complementing our existing coverage across US, EU and other Asian territories. 💡Optimal formulation identified, enhancing oral bioavailability and en … y studies, data from which will form an essential element of the clinical trial application next year. #Orexin #patentgrant #Ox -1 #innovation #addiction 30 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relevant Posts Hannah Gore 9mo Report this post Antibody patents just got a lot more complicated. With heightened written description requirements, genus claim limitations, and enablement hurdles creating new challenges, protecting antibody
Investegate | RNS | Company Announcements | Home | FTSE 100, 250, AIM, techMARK Fundraise Welcome About Contact Us Help Home Companies Advanced search Archive UK Short Positions Meetings UK Newswire New Login Register Search the UK's largest regulatory announcements database --> --> --> Advanced Search Sponsored By All FTSE 100 FTSE 250 AIM Aquis Asset Match JP Jenkins techMark My List Category Sector NAVs & Form8's Crypto News Show 50 100 200 300 entries Filter by source, company or headline Time Source Company Announcement 12 Dec 2018 07:00 AM RNS Diversified Energy Company (DEC) Change of A … EC) Director/PDMR Shareholding 12 Dec 2018 07:00 AM RNS Franchise Brands (FRAN) Grant of Share Options 12 Dec 2018 07:00 AM RNS Buccaneer Energy PLC (BUCE) Mesquite Field Development Plan 12 Dec 2018 07:00 AM RNS TheraCryf Plc (TCF) Interim Results 12 Dec 2018 07:00 AM RNS Baillie Gifford UK Growth Trust (BGUK) Half-year Report 12 Dec 2018 07:00 AM RNS EJF Investments Ltd NPV (EJFI) Corporate Update 12 Dec 2018 07:00 AM RNS NB Global Monthly Income Fund Limited Red Ord Shs NP
TheraCryf PLC (LSE:TCF) Share Price | Morningstar Skip to Content Search Home Markets Investments News and Insights Learn Products Solutions About Market Centre Australia United States Europe Asia Market Report ASX Market Report Roundup of ASX market movements Market Calendar Upcoming Dividends Dividend payments in the coming 90 days Discover Investments Investment Ideas Read the latest investing news and insights Top Stories Markets Personal Finance Retirement Stocks ETFs Funds Fixed Income Industry Insights Adviser Spotlight Manager Spotlight Firstlinks Investing content Investing guides Web
THERACRYF | Upcoming conferences Home StockRanks™ Platform Insights Research & Discuss Editorial & Community Learn & Improve Webinars & Masterclasses Stockopedia Academy Reviews Pricing Get started Log in Sectors Healthcare Biotechnology & Medical Research Theracryf TCF — Theracryf News Story 0.24p 0.00 0.00% Last trade - 00:00 Healthcare Highly Speculative Micro Cap Momentum Trap Market Cap £5.05m Enterprise Value £1.55m Revenue Quality Value Momentum Stock Rank ™ StockReport™ Accounts Balance sheet Income statement Cashflow statement Dividend summary News TCF Dividends St … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] (mailto:[email protected]) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further in
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 6 0 obj > stream x��]�v$�q��|E��ڇhU��� �f�c��f1��OƘg��� �L]�W�� �-5�Qj� =R�������ф�ƛkLY�)�����7 � j����-�uS� �'
TheraCryf News for Investors | TheraCryf plc Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us Investor Centre Our broad clinical and preclinical pipeline in brain disorders focuses on indications including addiction, anxiety, fatigue, narcolepsy and glioblastoma. 0.23 GBX Volume: 228,205 Market Capitalisation (m) £4.94 Diversified portfolio in high demand therapeutic areas Diversified portfolio in high demand therapeutic areas Focus on brain disorders Pre-clinical CNS pipeline in indications wi … ons with high unmet need – addiction, anxiety, narcolepsy Clinical stage, grant funded collaboration with Erasmus Medical Centre for SFX-01 in glioblastoma. Significant market potential Significant market potential Near clinic-ready CNS assets offer opportunity to build substantial value quickly Addiction market alone currently worth $40bn worldwide Out-licensing transactions at early and mid-stage development in the £00million range Lack of suitable drug candidates cur … record of effective company financing via both capital markets and non-dilutive grant funding TheraCryf plc Investor Presentation 03 - December - 2025 TheraCryf shares the latest corporate presentation following the release of the half-year report to 30 September 2025 Read more Focus IR Interview - Positive OX-1 Toxicology Results, Partner Interest & Human Trials 15 - May - 2026 Following the announcement of positive top-line toxicology data, CEO Dr Huw Jones joins John H
Appointment as Nominated Advisor and Broker to TheraCryf plc - Singer Capital Markets You are using an outdated browser. Please upgrade your browser to improve your experience. Call +44 (0)20 7496 3000 Email [email protected] SIREX (Log in) Get In Touch About us The Singer Way Our People Careers What we do Investment Banking Markets Client Success Stories Deal Activity Singer Social Impact Overview Greenhouse Sports IntoUniversity Chelsea FC Women Alantra Partnership Overview Thought Leadership Sunday Times 100: The Fastest-Growing Companies of 2026 Hundred Tech: The Companies Defining 20
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 50 0 obj > stream x�uTMo7���q���~ ��9i��m�,ڃу�ȶ[��| ��ovW� 2 �Cr��7s�؋c��/�:,5sl��*�,�0��vם j��r��n�]u�.� ��
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 6 0 obj > stream x��Y]s۸�����g J�l�G��e�Ԧj�������'V �}&�m�؋���>a�7�8�&q��HJi��ba�IB�$��:Od�Lfy�i���� FZq
TheraCryf | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas TheraCryf Website: Chronos Therapeutics Business Area(s) Neurobiology Description Neurodegenerative Therapies Career Page(s) Careers Company Location(s) Oxford United Kingdom body Sign up for news Contact Us Add an Employer About the Site Site's Purpose and Use Articles People in Biotech Biotech
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 6 0 obj > stream x��}͒ ɑ �r�p���$S5]������9k+i).�H�A7Э���t������!x��o��Q'������'����V˵AGVd�����G�w�ikV�
Contact TheraCryf | Oncology and behavioural brain disorders Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us Contact Please contact us via the appropriate email address or phone number listed below, or by completing the enquiry form. Careers TheraCryf has a small team that works with a wide network of highly qualified scientists, consultants and organisations to deliver our strategy. Please email [email protected] for further information. Name First Name Last Name Email Untitled Address
TheraCryf: European Patent Office to award patent for Ox-1 antagonist - Consumer, Life Science, Pharmaceutical Industry News - Zenopa UK Looks like you’re on the UK site. Choose another location to see content specific to your location Union Européenne – Français Europäische Union – Deutsch United States – English United Kingdom – English Save Zenopa Job Search Open menu Close Find a Job Find your perfect job with Zenopa. Use our advanced search tool to help find your next job in the US, EU or UK. Search all jobs Register with Us Send us your CV and requirements to allow us to find the p … onsumer Animal Health Roles Service Engineering Graduates Executive Find Talent Submit a brief and find the best talent across the US, EU and UK. Zenopa recruits top talent across the US, EU and UK. Submit your job and a member of the Zenopa team will be in contact with you shortly. Post a Job Permanent Roles Contact a member of our team now to discuss how we can help you fill your permanent roles in the US, EU and UK Contract Roles Contact a member of our team now to discuss … Log In Region Home Industry News Consumer TheraCryf: European Patent Office to award patent for Ox-1 antagonist TheraCryf: European Patent Office to award patent for Ox-1 antagonist 28th November 2024 Alderley Park, UK – 27 November 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry has received the decision from the European Patent Office to award a Composition of Matter patent for its Orexin 1 (Ox-1) recept … ter patent for its Orexin 1 (Ox-1) receptor antagonist in Europe, with a formal grant to be made on 18 December 2024. TheraCryf’s highly selective Ox-1 receptor antagonist was acquired as part of its acquisition of Chronos Therapeutics Ltd in April 2024. An imbalance in Orexin production and stimulation of the Orexin 1 receptor in the brain has been linked to anxiety, addiction and other mental health conditions. An Orexin 1 receptor antagonist inhibits the effect of Orexin o … d Receive the latest industry news, Tips and straight to your inbox. Your email Submit By subscribing you agree to our terms and conditions. Share Article Share on Twitter Share on Facebook Share on LinkedIn Copy link Copied to clipboard Sign Up Receive the latest industry news, and job vacancies relevant to you, straight to your inbox. Your emai
TheraCryf Plc - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 06 Dec 2025 TheraCryf Plc Public Company | 2007 | United Kingdom | < 10 | LON: TCF | www.evgen.com Public Company | 2007 | United Kingdom | < 10 | LON: TCF | www.evgen.com Last update 06 Dec 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Nervous System Diseases Neoplasms Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data Techn … delivery device attached to the patient’s abdomen. Andera Raises $442M for New Fund Life science venture capital firm Andera Partners announced Monday that it had raised around $442 million for the sixth generation of its BioDiscovery fund. The money will be used to build the venture’s portfolio of biopharma companies working on innovative treatments and medical technologies across all stages of development. So far, BioDiscovery 6 has already invested in Imcheck, Mineralys, … um, corresponding to a price of $4.35 per share. The proceeds will help Immunic fund its current clinical development projects, particularly its three lead oral immunology candidates: IMU-838 (vidofludimus calcium) for multiple sclerosis, IMU-935 for psoriasis and castration-resistant prostate cancer and IMU-856 for conditions associated with bowel barrier dysfunction. The PIPE money, together with current cash, cash equivalents and marketable securities, will see Immunic thr … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Experienced life sciences executive, Dr Alastair Smith, appointed Chair - BioUK Skip to content 120) ? true : false"> Search Login Join BioUK About What we do Our Culture Meet The Team Sponsors and Supporters P&CAG ITAG Contact Membership Benefits & Savings Join BioUK BioUK Go2Guides Members Directory Events & Coaching BioUK Events BioUK Coaching 1:1 Coaching BioLearn Event Resources Member Events Event Discounts Purchasing & Savings Overview Suppliers Event Discounts Consultancy Business Support Partner4Pharma News Jobs About What we do Our Culture Meet The Team Sponsors and Supporters P&CAG … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the Lo
TheraCryf PLC (TCF) Stock, Price, News, Quotes, Forecast and Insights | MSN Money Popular NIO ▲ +1.06% BTC ▲ +0.99% W1DOW ▼ -0.28% ETH ▲ +1.24% BNB ▲ +2.30% DJI ▼ -0.18% RIOT ▲ +1.01% ADA ▲ +4.58% ALXIL ▲ +4.32% MSFT ▲ +5.14% My watchlist Suggested for you NIO Inc NIO 4.78 +1.06% Bitcoin BTC 52,568.30 +0.99% Dow Jones Global Index W1DOW 827.17 -0.28% Ethereum ETH 1,385.41 +1.24% BNB BNB 497.04 +2.30% DOW DJI 51,827.30 -0.18% Riot Platforms Inc RIOT 28.04 +1.01% Cardano ADA 0.13 +4.58% Xilam Animation SA ALXIL 5.80 +4.3
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 32 0 obj > stream x�MSKo�0 ��W�H�+��Ҵk����a��p���M�lؿ i'M ����H~$�B�(���dt�N�D2 1EM�J�$vˌ��WJ8K�]�-��mf��̽�.
TheraCryf | A clinical stage therapeutics company Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us Welcome to TheraCryf plc Developing innovative therapeutics in brain disorders TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Behavioural brain disorders such as opioid and alc … s working in collaboration with Erasmus Medical Centre Rotterdam, NL on a fully grant funded programme to bring SFX-01 to patients with glioblastoma. Strategy TheraCryf’s strategy is to demonstrate proof of concept for its proprietary drug candidates in carefully selected diseases and then conclude partnerships with larger organisations better positioned to take these drugs through large scale clinical trials and commercial launch. Read more Science TheraCryf's class-leading
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> TheraCryf PLC (LON: TCF) Share Price | RNS News, Quotes, & Charts | TCF.L | @ element('Front/sign_in_out_buttons') --> CA UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news CSE Markets Live OTC Markets Small caps Market movers: Triller Group, Eli Lilly, Onsemi… 14:30 26 Jun --> Lululemon shares rise after shareholders approve board slate in settlement with founder 12:05 26 Jun --> OTC Markets Group welcomes Nevada King Gold to OTCQX Best Market 09:34 26
TheraCryf Pipeline - TheraCryf Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us Our Pipeline Discovery Pre-clinical POC CTA / IND Enabling Phase 1 Phase 2 Ox-1 - Substance Use Disorders (SUDs) / Anxiety TheraCryf has Ox-1, a candidate orexin-1 antagonist (blocker), targeting SUDs and anxiety with preclinical proof of concept in a model of Binge Eating Disorder (BED). Orexin antagonists have already demonstrated preliminary effectiveness in man. Read more DAT - Fatigue and Narcolepsy TheraCryf h … orthotopic models of Glioblastoma. Further preclinical work is underway under a grant to the Erasmus Medical Centre, Rotterdam, NL. A window of opportunity clinical study is being designed under the same grant. Read more SFX-01- Neurodevelopmental Disorders TheraCryf has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla Read more Licensing & Partnerships Licensing Strategy TheraCryf is open to out-licensing and … molecular targets in excised tumour tissue. The studies, which are funded by a grant awarded by the KWF Dutch Cancer Society, formally commenced on 1 October 2023. The US Food and Drug Administration (”FDA”) has granted an Orphan Drug Designation (“ODD”) for the use of SFX-01 to treat malignant glioma. This is usually granted when there are fewer than 200,000 patients with a given disease in the United States and there is a scientific rationale for po … ional drug in the form of data protection at the time of approval of a new drug application, which is additional to any patent cover in force. Tax credits are also possible on eventual US sales of an approved orphan drug. SFX-01 - Neurodevelopmental Disorders + - Autism spectrum disorder is a group of neurodevelopmental disorders (NDDs) currently diagnosed based on core behavioural features, without specific biological criteria. Previous studies with other sources of sulforap
--> Chronos identifies the benefits of pharmaceutical collaboration – European CEO --> Search for: --> Sign up for the newsletter › --> › Digital Editions Profiles Industry Outlook Management Finance World View Lifestyle Videos Awards Search for: MENU Profiles Industry Outlook Management Finance World View Lifestyle Videos Awards Digital Editions Chronos identifies the benefits of pharmaceutical collaboration Collaboration is opening up new opportunities in the pharmaceutical industry, though political shifts are threatening the funding base that supports smaller pla … facilities. In addition, most Big Pharma companies have a strategic investment fund where they can invest in SMEs that have promising early technologies which may be of interest down the line. Positive pressure for innovation creates a considerable opportunity for SMEs, as they are in a position to take more risk and act quickly Other models include licensing out earlier stage projects or those outside of a company’s scope to smaller firms. A recent example of this collabora … s for developing its high risk R&D, including an EU Horizon 2020 consortium grant that is about to start. What effect could Brexit have on grant funding from the UK and the EU? The answer today is that Brexit creates considerable uncertainty over the potential flow of non-dilutive capital in the future. Existing grants are safe, but the position on new grant money over the next three years is largely unknown. Both EU and UK bodies need to preserve the positive R&D par
%PDF-1.5 %���� 358 0 obj > endobj xref 358 69 0000000016 00000 n 0000002582 00000 n 0000002696 00000 n 0000004061 00000 n 0000004688 00000 n 0000005481 00000 n 0000005950 00000 n 0000006096 00000 n 0000006193 00000 n 0000006307 00000 n 0000006419 00000 n 0000006508 00000 n 0000007045 00000 n 0000007748 00000 n 0000008468 00000 n 0000008553 00000 n 0000009009 00000 n 0000009570 00000 n 0000010202 00000 n 0000011716 00000 n 0000012917 00000 n 0000012954 00000 n 0000014258 00000 n 0000015111 00000 n 0000015927 00000 n 0000016974 00000 n 0000018409 00000 n 0000019641 00000 n 0000023538 00000 n 000 … dobj 396 0 obj > endobj 397 0 obj > endobj 398 0 obj > endobj 399 0 obj >stream application/pdf logo_30_years_eano_vertical_circle_02 2024-07-18T11:41:46+02:00 2024-07-18T11:41:46+02:00 2024-07-18T11:41:46+02:00 Adobe Illustrator 28.5 (Macintosh) uuid:e2749761-b643-ff47-a3d1-cf2e35fca99e xmp.did:c021b509-1b04-5f48-9e61-5edc87ce2f48 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:a581a5a9-dfc1-49a9-970f-ad4cff0b0e7c xmp.did:eb4e7f1d-3c0c-014f-9a85-957b33d42b9c uuid:5D2089 … �m��h�G�E�,Kl�.����ic�A�+ �"�n��_ �� ��%/ `���^�� ����>�u�W>��Z{F >stream application/postscript glasgow-convention-bureau-logo-black Varga, Zsuzsa 2019-06-03T14:57:40+01:00 2019-06-03T14:57:40+01:00 2019-06-03T14:57:40+01:00 Adobe Illustrator CC 23.0 (Windows) xmp.iid:3bf500c4-cf37-2447-aded-2ece1def8010 xmp.did:3bf500c4-cf37-2447-aded-2ece1def8010 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:5ac68843-d119-4aa1-a8c7-d05c2414b7bd xmp.did:5ac68843-d119-4aa1-a8 … d 2018-06-26T12:02+01:00 Adobe Illustrator CC 22.1 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3bf500c4-cf37-2447-aded-2ece1def8010 2019-06-03T14:57:40+01:00 Adobe Illustrator CC 23.0 (Windows) / Print False False 1 675.018005 338.983002 Pixels Black Default Swatch Group 0 Adobe PDF library 15.00 endstream endobj 4 0 obj > endobj 5 0 obj >stream endstream endobj 6 0 obj >stream ����Adobed��� … ��e�iq��ڣ�� ^3�5|� �k�dϨ� �ayF�ڌ���׆,�RZ�/ژCby�S�UY� f�?`�� $�aj�� >stream application/postscript Druck Barbara Biegl 2017-07-04T11:39:35+02:00 2017-07-04T11:39:35+02:00 2017-07-04T11:39:35+02:00 Adobe Illustrator CC 2015 (Macintosh) xmp.iid:338cf84c-e718-4fa7-a87c-9875dca71165 xmp.did:338cf84c-e718-4fa7-a87c-9875dca71165 uuid:5D20892493BFDB
TheraCryf's DAT Inhibitor Shows Promise in Mental Fatigue Treatment | Capital Access posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … urnal by Bentham Science , invites researchers and pharmaceutical scientists to submit full-length reviews, mini-reviews, drug clinical trial studies, and guest-edited thematic issues focusing on molecular drug targets. 🔗 𝐒𝐮𝐛𝐦𝐢𝐭 𝐲𝐨𝐮𝐫 𝐦𝐚𝐧𝐮𝐬𝐜𝐫𝐢𝐩𝐭: https://bit.ly/4qH9Y9g 👤 𝐄𝐝𝐢𝐭𝐨𝐫-𝐢𝐧-𝐂𝐡𝐢𝐞𝐟: Hao Lin 📅 𝐈𝐦𝐩𝐚𝐜𝐭 𝐅𝐚𝐜𝐭𝐨𝐫: 2.5 | 𝐂𝐢𝐭𝐞𝐬𝐜𝐨𝐫𝐞: 7.2 We’re proud to collaborate with leading experts Eva L. Feldman, M.D., Ph.D. , Mandeep Kau … ers 5mo Report this post SFBN Feed: Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors https://lnkd.in/gT2sZ3Re PHILADELPHIA & SAN FRANCISCO–(BUSINESS WIRE)–Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s [...] #BayArea #SanF … ancisco #Biotech #Lifescience #News Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors https://sfbn.org Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in MassBio 48,899 followers 5mo Report this post Innovation at biopharma companies in Massachusetts didn't stop last year. During the most challenging period in recent memory for financings and exits, they expanded the pipeli … hile no formal offer has been confirmed and regulatory scrutiny in France would apply, the news underscores ongoing M&A momentum in immunology and late-stage biotech pipelines. 💡 Why it matters: This move underscores continued consolidation interest in mid-to-late-stage biotech companies with compelling clinical assets. For Lilly, acquiring
%PDF-1.7 %���� 293 0 obj > endobj xref 293 18 0000000016 00000 n 0000001651 00000 n 0000001868 00000 n 0000001912 00000 n 0000002286 00000 n 0000002919 00000 n 0000002956 00000 n 0000003070 00000 n 0000003167 00000 n 0000003819 00000 n 0000004511 00000 n 0000006095 00000 n 0000006392 00000 n 0000009041 00000 n 0000014207 00000 n 0000015252 00000 n 0000015549 00000 n 0000000656 00000 n trailer ]/Prev 450368>> startxref 0 %%EOF 310 0 obj >stream h�b```b``���dH2�1 +P��a� ėt� �����)�����D}� in ���]��dx �4C�H'ćI������ThF�&�w|7̈́��@����ĥa��&�b��>����T�ĦrCp�+fbÝ��.���b�4�%��t7�А … 14e14815188 xmp.did:195a2fd8-8937-4b3d-9b9a-27918ee562f2 default converted from application/x-indesign to application/pdf Adobe InDesign CC 2015 (Macintosh) / 2015-10-09T14:16:29+01:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 292 0 obj > endobj xref 0 293 0000000000 65535 f 0000015900 00000 n 0000016282 00000 n 0000020385 00000 n 0000020767 00000 n 0000022828 00000 n 0000023144 00000 n 0000023365 00000 n 0000023748 00000 n 0000026216 00000 n 0000026636 00
Our portfolio of companies | Oxford University Innovation Skip to main content About us What we do How we work Meet the team Our leadership University partnership Our innovation ecosystem Impact driven Careers News & events Contact us Search Get started Is my idea ready? What kind of support is available? What happens when I contact OUI? Submit your idea Be inspired Protect my idea What is IP? Protect first, then publish Who owns what at Oxford? Licensing Clinical Outcome Assessments Grow my idea Translational funding How to access funding Preparing to pitch Create a company Is a new compa … idea ready? What kind of support is available? What happens when I contact OUI? Submit your idea Be inspired Protect my idea What is IP? Protect first, then publish Who owns what at Oxford? Licensing Clinical Outcome Assessments Grow my idea Translational funding University Challenge Seed Fund (UCSF) How to access funding Preparing to pitch Create a company Is a new company right for me? What happens to IP? How OUI supports Founders Incubator support Building a team Getting i
%PDF-1.4 %�쏢 %%Invocation: path/gs -P- -dSAFER -dCompatibilityLevel=1.4 -q -P- -dNOPAUSE -dBATCH -sDEVICE=pdfwrite -sstdout=? -sOutputFile=? -P- -dSAFER -dCompatibilityLevel=1.4 -dAutoRotatePages=/None -dPDFSETTINGS=/ebook -dDetectDuplicateImages=true %%+ -dEmbedAllFonts=true -dSubsetFonts=true -dCompressFonts=true -dNOPAUSE -dQUIET -dBATCH -f ? 32 0 obj > stream x��[َ DZm�O��@=�p7�)��[�dj�dq8�|u��ER��8�m���a>'r��)q� �3�љ����Ȫy=�YO���������j����c���i����������?�x��ۧ�\[7���[|���7[5;����O����[����9�ɛ`f禠�� n�m u��.��� #�ܜ�� H\�"�NT|���A��e��+�/�M������+�x��'��g�(�Y���OK{���W
TheraCryf Plc RNS Announcements | TCF RNS Announcements | Investegate Fundraise Welcome About Contact Us Help Home Companies Advanced search Archive UK Short Positions Meetings UK Newswire New Login Register Search the UK's largest regulatory announcements database --> --> --> Advanced Search Sponsored By Announcements Price Short Positions Fundamentals News --> TheraCryf Plc (TCF) RNS Announcements Add to Alert list Show 50 100 200 300 entries Filter by source or headline Date Time Source Announcement 17 Jul 2002 07:00 AM RNS Director Shareholding 12 Jul 2002 09:39 AM RNS Director Shareholdin
%PDF-1.4 %���� 505 0 obj > endobj xref 505 82 0000000016 00000 n 0000002434 00000 n 0000002536 00000 n 0000003135 00000 n 0000003251 00000 n 0000003288 00000 n 0000003402 00000 n 0000004564 00000 n 0000005637 00000 n 0000006700 00000 n 0000007769 00000 n 0000008794 00000 n 0000009379 00000 n 0000009406 00000 n 0000009894 00000 n 0000009921 00000 n 0000010060 00000 n 0000010200 00000 n 0000011197 00000 n 0000011339 00000 n 0000011366 00000 n 0000012033 00000 n 0000013256 00000 n 0000014301 00000 n 0000014737 00000 n 0000014807 00000 n 0000015065 00000 n 0000019160 00000 n 0000021809 00000 n 000 … 835]>>stream H�4�; �P���b6��̼_� b).@�*Jt�`9���Uٌ2;� �9�tXɆ�#nx���J >stream application/postscript Adobe Illustrator CS3 2014-12-18T21:47:18Z 2014-12-18T21:47:21Z 2014-12-18T21:47:21Z 256 180 JPEG /9j/4AAQSkZJRgABAgEBLAEsAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABABLAAAAAEA
AQEsAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f … �9:�_g��q�p;�4zJJ�^����27�l�K��U�ў�)x�\���n���v�c��/����=+gE�ʴp/��*s��rfp��D˙a�w�t�W-q��0���ЛM���������du�ش�O� ��`z� ���)k/�A�G]��e������C�4��oW��� � ��{s��u�ǡ��Kdm��9�I�%�!��X\qfU��e��!� �����9� ������wʚ놧�նZ�{���.C�V��裍� ?�����[� d�֫�1�۷F. �'��g�/��K鿓�����bCZ� 2 �� ��1 ���� �1V��0]M�ۯ�>h*�1'�����Zj�J�� P��f�,B�f��2x�ڤ���]JܭRne�O��Q`/����j���A�$�П&��̏���~��m�7C?���(�o2�����n���5��{p������$BLB ���q!1����s5 ����A�q72q^�o��H���}ތ�;��%���� p[ … �����C�H�9�l��r�N�2�8 endstream endobj 396 0 obj > endobj 397 0 obj >stream application/postscript Print Adobe Illustrator CS3 2016-09-09T09:51:04+01:00 2016-09-09T09:53:47+01:00 2016-09-09T09:53:47+01:00 256 72 JPEG /9j/4AAQSkZJRgABAgEBLAEsAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABABLAAAAAEA
AQEsAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8f … D9iqf/AEok
pgfrL9T3WC09V6abBw85FG7796PEapHCLtn/AM7Pqr/5c9P/APYqn/0ogl//2Q== application/pdf Adobe PDF Library 8.0 False endstream endobj 504 0 obj > endobj xref 0 505 0000000000 65535 f 0000292690 00000 n 0000293296 00000 n 0000299891 00000 n 0000299964 00000 n 0000313735 00000 n 0000314230 00000 n 0000314274 00000 n 0000315086 00000 n 000031
TheraCryf is advancing the treatment of high unmet need Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us How TheraCryf is focusing on innovative therapies for brain diseases TheraCryf is developing novel medicines to help people with brain disorders and is focusing initially on addiction. The lead programme is a class-leading orexin-1 antagonist, initially targeting binge eating disorder, with an aim to be clinic ready in 2026. The second programme addresses fatigue with a novel dopamine transp … programme, SFX-01, is a clinical stage asset that is being advanced via a fully grant funded collaboration with Erasmus Medical Centre in Rotterdam, in the fatal brain cancer glioblastoma* (GBM). *orphan indication TheraCryf's priority product: OX-1 TheraCryf’s priority programme is a best in class orexin-1 receptor antagonist (blocker) that is being developed towards the clinic to target addictive behaviours like binge eating disorder (BED). Orexin has a ro … nced through collaboration with Erasmus Medical Centre Rotterdam, NL on a fully grant funded programme to bring SFX-01 to patients with glioblastoma. STAT3 and pSTAT3 – STAT3 (signal transducer and activator of transcription 3) and phospho STAT3 (pSTAT3) has importance in controlling cancer metastases. Malfunction in these pathways has been implicated in a number of cancers including breast cancer. Research is ongoing into the role of SFX-01 and its inhibition of STAT3/
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Operating Partners Forum: Europe 2021 | Join top PE value creators Contact us Global Events Calendar Infrastructure Investor events PDI events PEI events PERE events PF CFO events Responsible Investor events Sustainability & Impact Events Networks Home Virtual experience Networking Agenda Speakers Sponsors Resources FAQs Book Now Home Virtual experience Networking Agenda Speakers Sponsors Resources FAQs Contact us Global Events Calendar Infrastructure Investor events PDI events PEI events PERE events PF CFO events Responsible Investor events Sustainability & Impact Events Networks Book … of the following you might be interested in: Sponsorship Attendance By clicking submit you consent to our terms & conditions and privacy policy . Request Download Loading form. Please wait. Select which of the following you might be interested in: Sponsorship Attendance By clicking submit you consent to our terms & conditions and privacy policy . Download Resource Request Download Loading form. Please wait. Select which of the following you might be interested in: Spo … of the following you might be interested in: Sponsorship Attendance By clicking submit you consent to our terms & conditions and privacy policy . Download Resource Request Download Loading form. Please wait. Select which of the following you might be interested in: Sponsorship Attendance By clicking submit you consent to our terms & conditions and privacy policy . Download Resource Request Download Loading form. Please wait. Select which of the following you might be … of the following you might be interested in: Sponsorship Attendance By clicking submit you consent to our terms & conditions and privacy policy . Download Resource Request Download Loading form. Please wait. Select which of the following you might be interested in: Sponsorship Attendance By clicking submit you consent to our terms & conditions and privacy policy . Download Resource Frequently asked questions We understand that the world of virtual events is a new one, … can and Asian businesses. A current judge of the UK’s “Entrepreneur of the Year Award” at the Lloyds Bank National Business Awards. His career has taken him to 51 countries and brings practical insight into the real-world challenges an investor and/or portfolio company manager faces with cross-border growth and alliances in different cultures. El
TheraCryf | A clinical stage therapeutics company Science Pipeline About Us News & Media Resources Investors Contact Us Science Pipeline About Us News & Media Resources Investors Contact Us Welcome to TheraCryf plc Developing innovative therapeutics in brain disorders TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Behavioural brain disorders such as opioid and alc … s working in collaboration with Erasmus Medical Centre Rotterdam, NL on a fully grant funded programme to bring SFX-01 to patients with glioblastoma. Strategy TheraCryf’s strategy is to demonstrate proof of concept for its proprietary drug candidates in carefully selected diseases and then conclude partnerships with larger organisations better positioned to take these drugs through large scale clinical trials and commercial launch. Read more Science TheraCryf's class-leading
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> TheraCryf shares rise 23% after biotech rejects takeover approach for neuropsychiatry assets | AIM:TCF @ element('Front/sign_in_out_buttons') --> USA UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news Live Market reports OTC Markets Small caps Market movers: Triller Group, Eli Lilly, Onsemi… 14:30 26 Jun --> Dow Jones leads Wall Street higher as dip buyers strike, oil prices under pressure 14:30 26 Jun --> IBM quantum foundry plan adds to long-term hard … ch disclosed it had received and rejected a conditional, non-binding indicative proposal to acquire its lead neuropsychiatry assets. The board unanimously concluded that the approach, which targeted the company's Orexin-1 (Ox-1) receptor blocker and dopamine transporter programmes, did not reflect the current or future value of the assets and was not in the best interests of shareholders. The Ox-1 programme, being developed as a treatment for addiction, is fully funded to gen … fully funded to generate all data required to support a Phase 1 clinical trial application by the fourth quarter of 2026. TheraCryf is targeting the addiction treatment market, which it estimates to be worth $42 billion. Chief executive Huw Jones said the board was confident the best route to delivering shareholder value was to continue developing its lead assets, and described the approach as encouraging evidence that the assets were attracting commercial attention. Jones p
--> Podcasts make radio the future of advertising – European CEO --> Search for: --> Sign up for the newsletter › --> › Digital Editions Profiles Industry Outlook Management Finance World View Lifestyle Videos Awards Search for: MENU Profiles Industry Outlook Management Finance World View Lifestyle Videos Awards Digital Editions Podcasts make radio the future of advertising As companies rush to partner with popular podcasts, a unique form of trusted storytelling is creating advertisements people actually want to hear, Podcasts are redefining audio entertainmen … ic medium Famous car adverts from 1920-1950 Publicis and Omnicom to join forces Rolling in the money Ian Penrose on the Littlewoods Casino | Sportech | Video Reading club About Us Contributors --> Contact Advertise Profiles Industry Outlook Management Finance World View Lifestyle Videos Awards --> -->
Department Family Name:,Department of Business Innovation & Skills,,,,, ,,,,,, Entity:,Technology Strategy Board,,,,, ,,,,,, ,,,,,, Expense Type,Expense Area,Transaction Reference 1,Transaction Reference 2,Vendor Name,Entry Date, Amount Grant Expense,Programme & Support Costs - Do not Use in Compleat,5,74644-501428,INNOVATIVE TECHNOLOGY AND SCIENCE LIMITED,13/07/2018,"25,008.61" Grant Expense,Programme & Support Costs - Do not Use in Compleat,3,92039-556178,THALAMUS AL LTD,20/07/2018,"25,023.34" Grant Expense,Programme & Support Costs - Do not Use in Compleat,8,62951-453278,TWI LTD,20/07/2018, … rt Costs - Do not Use in Compleat,8,62951-453278,TWI LTD,20/07/2018,"25,068.81" Grant Expense,Programme & Support Costs - Do not Use in Compleat,2,640009,GWE BUSINESS WEST LTD,05/07/2018,"25,083.00" Grant Expense,Programme & Support Costs - Do not Use in Compleat,1,6660,FLUIDLY LIMITED,20/07/2018,"25,218.83" Grant Expense,Programme & Support Costs - Do not Use in Compleat,1,97526-566343,TRANSPORT DESIGN INTERNATIONAL LTD,05/07/2018,"25,273.58" Grant Expense,Programme & Suppor … not Use in Compleat,3,92138-556187,UNIVERSITY OF GLASGOW,05/07/2018,"25,352.83" Grant Expense,Programme & Support Costs - Do not Use in Compleat,2,400,JELLY PRODUCTS LTD,05/07/2018,"25,374.71" Grant Expense,Programme & Support Costs - Do not Use in Compleat,4,70971-492147,LANCASTER UNIVERSITY,05/07/2018,"25,392.39" Grant Expense,Programme & Support Costs - Do not Use in Compleat,6,77148-510196,AMAPHASE LTD,20/07/2018,"25,397.98" Grant Expense,Programme & Support Costs - Do no … Use in Compleat,4,81163-513165,GREATER LONDON AUTHORITY,05/07/2018,"25,421.92" Grant Expense,Programme & Support Costs - Do not Use in Compleat,1,4843,CAMBRIDGE RESPIRATORY INNOVATIONS LTD,20/07/2018,"25,553.02" Grant Expense,Programme & Support Costs - Do not Use in Compleat,7,E!10619,TRITEQ LIMITED,13/07/2018,"25,583.44" Grant Expense,Programme & Support Costs - Do not Use in Compleat,3,89396-549428,UNIVERSITY OF THE WEST OF SCOTLAND,13/07/2018,"25,967.11" Grant Expense,Pr … not Use in Compleat,4,77890-503994,UNIVERSITY OF ULSTER,20/07/2018,"26,025.46" Grant Expense,Programme & Support Costs - Do not Use in Compleat,5,83808-533144,EQUIPMAKE LTD,13/07/2018,"26,056.35" Grant Expense,Programme & Support Costs - Do not Use in Compleat,2,E!11406,Cell Guidance Systems Limited,20/07/2018,"26,086.60" Grant Expense,Programme